@article {YAMAMOTO1873, author = {YOSHIHIRO YAMAMOTO and KAZUSHI WATANABE and IKUTO TSUKIYAMA and HIROMITSU YABUSHITA and KATSUHIKO MATSUURA and AKIHIKO WAKATSUKI}, title = {Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (>=50 mg/m2) Combination Chemotherapy}, volume = {36}, number = {4}, pages = {1873--1877}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: We aimed to assess whether the efficacy of pre-hydration with 15 mEq magnesium prevents cisplatin-induced nephrotoxicity in cisplatin regimens (dosage: 50 mg/m2 or more) for gynecological cancer. Patients and Methods: This historical, prospective cohort study compared nephrotoxicity in patients who received pre-hydration with or without magnesium sulfate (Mg-hydration group, n=37; non-Mg-hydration group, n=37). We used serum creatinine (Scr), creatinine clearance (Ccr) and Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) criteria. Results: A change of Scr and Ccr in the Mg-hydration group was higher than in the non-Mg-hydration group. Based on the RIFLE criteria, the number of moderate renal dysfunction patients classified as {\textquotedblleft}Risk{\textquotedblright} in the Mg-hydration group was significantly lower than in the non-Mg-hydration group (Mg-hydration group=21.6\%; non-Mg-hydration group=51.4\%; p\<0.01). Serum magnesium levels in the Mg-hydration group significantly declined during chemotherapy (p\<0.01). Conclusion: We found that a 15 mEq magnesium as pre-hydration provided nephroprotective effects in patients receiving this cisplatin regimen. Future research should involve finding appropriate magnesium doses.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/4/1873}, eprint = {https://ar.iiarjournals.org/content/36/4/1873.full.pdf}, journal = {Anticancer Research} }